Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models.
cabozantinib
colorectal cancer
humanized mouse model
immune checkpoint blockade
immunotherapy
nivolumab
tumor immunology
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
02
2022
accepted:
17
10
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors have been found to be effective in metastatic MSI-high colorectal cancers (CRC), however, have no efficacy in microsatellite stable (MSS) cancers, which comprise the majority of mCRC cases. Cabozantinib is a small molecule multi-tyrosine kinase inhibitor that is FDA approved in advanced renal cell, medullary thyroid, and hepatocellular carcinoma. Using Human Immune System (HIS) mice, we tested the ability of cabozantinib to prime MSS-CRC tumors to enhance the potency of immune checkpoint inhibitor nivolumab. In four independent experiments, we implanted distinct MSS-CRC patient-derived xenografts (PDXs) into the flanks of humanized BALB/c-Rag2
Identifiants
pubmed: 36419897
doi: 10.3389/fonc.2022.877635
pmc: PMC9676436
doi:
Types de publication
Journal Article
Langues
eng
Pagination
877635Informations de copyright
Copyright © 2022 Lang, Leal, Marín-Jiménez, Hartman, Shulman, Navarro, Lewis, Capasso, Bagby, Yacob, MacBeth, Freed, Eckhardt, Jordan, Blatchford, Pelanda, Lieu, Messersmith and Pitts.
Déclaration de conflit d'intérêts
Exelixis supplied cabozantinib and funded this study, with TP as Principal Investigator, but had no role in study design, data collection, data analysis, data interpretation, or writing of the report. WM is the principal investigator of a phase II clinical trial of cabozantinib in patients with refractory metastatic colorectal cancer that is sponsored by Exelixis NCT03542877. AL is the principal investigator of a phase II clinical trial of cabozantinib in combination with nivolumab in metastatic colorectal cancer which is co-sponsored by Bristol Myers Squibb and Exelixis NCT04963283. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217760
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Immunity. 2010 Aug 27;33(2):229-40
pubmed: 20727791
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Acta Oncol. 2009;48(4):591-7
pubmed: 19330565
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Immunother Cancer. 2019 Feb 8;7(1):37
pubmed: 30736857
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
J Clin Oncol. 2020 Jun 20;38(18):2053-2061
pubmed: 32343640
Clin Cancer Res. 2017 Nov 1;23(21):6650-6660
pubmed: 28751450
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Leukemia. 2010 Oct;24(10):1785-8
pubmed: 20686503
Br J Cancer. 2009 Jan 27;100(2):266-73
pubmed: 19165197
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33045061
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Med Sci Monit. 2015 Aug 08;21:2316-21
pubmed: 26255947
Front Immunol. 2021 Mar 29;12:607282
pubmed: 33854497
Mol Cancer Ther. 2018 Oct;17(10):2112-2122
pubmed: 30026382
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Blood Adv. 2017 Dec 19;1(27):2729-2741
pubmed: 29296925
Int J Cancer. 2015 Apr 15;136(8):1967-75
pubmed: 25242168
Lancet Oncol. 2020 Aug;21(8):1099-1109
pubmed: 32645282
J Immunol. 2013 Mar 1;190(5):2090-101
pubmed: 23335750
J Transl Med. 2014 Nov 13;12:294
pubmed: 25388653
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Clin Endocrinol Metab. 2020 Jan 1;105(1):
pubmed: 31513709
Front Immunol. 2018 Jan 15;8:1970
pubmed: 29379506
Cold Spring Harb Perspect Biol. 2019 Mar 1;11(3):
pubmed: 29661791
Cancer Res. 2007 Apr 15;67(8):3970-5
pubmed: 17440113
Annu Rev Immunol. 2013;31:635-674
pubmed: 23330956
J Vis Exp. 2016 Sep 30;(115):
pubmed: 27768028
Nat Commun. 2018 Nov 28;9(1):5031
pubmed: 30487575
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Ann Oncol. 2017 Dec 01;28(12):3044-3050
pubmed: 28950298
Clin Immunol. 2011 Jul;140(1):102-16
pubmed: 21536497
FASEB J. 2018 Mar;32(3):1537-1549
pubmed: 29146734
Immunology. 2018 May;154(1):50-61
pubmed: 29446074
Lancet Oncol. 2019 Jun;20(6):849-861
pubmed: 31003911
Mol Oncol. 2018 Oct;12(10):1797-1810
pubmed: 30120895
Cancer Med. 2018 Sep;7(9):4509-4516
pubmed: 30039553
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050